2018 American Transplant Congress
Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipients
BACKGROUND: Donor specific antibodies (DSA) have been implicated in the development of acute rejection (AR) and graft dysfunction in kidney transplant recipients (KTx). However, limited…2018 American Transplant Congress
Safety and Efficacy of Tocilizumab (anti-IL6R, TCZ) Therapy in the Treatment of Chronic Antibody Mediated Rejection (cABMR) in Pediatric Renal Transplant Recipients
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA.
Background: Development of de novo Donor specific antibodies (DSA) post renal transplantation puts pediatric patients(pts) at risk for ABMR and allograft failure (Kim JJ AJT…2018 American Transplant Congress
Follow Up of Patients Treated with the IgG Endopeptidase (IdeS) for Desensitization and HLA Incompatible (HLAi) Kidney Transplantation
Introduction:Donor-specific antibodies (DSAs) create an immunologic barrier to transplantation. This prevents transplantation for a significant percentage of highly-HLA sensitized patients (HS). Current desensitization therapies are…2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…2018 American Transplant Congress
Acute Antibody Mediated Rejection Treatment Impact on Class I and Class II Anti-HLA Antibodies in Pediatric Kidney Transplant Recipients
Purpose: Characterize class I and class II donor specific antibodies (DSA) response to acute antibody mediated rejection (AMR) treatment in pediatric kidney transplant recipients (KTR).Methods:…2018 American Transplant Congress
No Deleterious Effect from the Presence of Donor Specific Antibodies (DSA) or Positive Flow Cytometry Crossmatch (FCXM) on the Outcomes of Simultaneous Liver-Kidney (SLK) Transplant Recipients
SLK transplant recipients have excellent outcomes that rival kidney alone recipients in terms of graft and patient survival and have better outcomes in terms of…2018 American Transplant Congress
Combination Proteasome Inhibition and Anti-BAFF Therapy Permits Highly Sensitized Rhesus Kidney Transplantation
Duke Transplant Center, Duke University Medical Center, Durham, NC.
Purpose:HLA-sensitization is a significant immunologic barrier to successful kidney transplantation (KT). We have shown that proteasome inhibition (PI) in insolation reduces plasma cells (PCs), but…2018 American Transplant Congress
Effect of HLA Antibodies on Graft Survival in Adult Live Donor Liver Transplantation
The relevance of HLA antibodies in liver transplantation is currently being re-evaluated. While hyperacute rejections are not an issue, antibody effects on long-term outcomes are…2018 American Transplant Congress
Comparison of C1Q Binding and Flow Cytometric Crossmatch Results Provides an Accurate Evaluation of Hypersensitive Kidney Transplant Patients
Measurement of C1q binding to Donor specific antibodies (DSA) gives transplantation chance to hypersensitive patients having non-binding high amount of anti-HLA antibodies. In our series…2018 American Transplant Congress
The Impact of Rapamycin Conversion in Pediatric Liver Transplantation on Anti-HLA Antibody Formation and Allograft Fibrosis
Background: Maintenance immunosuppression with tacrolimus (TAC) is associated with progressive liver allograft fibrosis. Conversion to rapamycin (RAPA) may abrogate this progression. The development of donor-specific…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 47
- Next Page »